Clinical trials
Concurrent Chemoradiotherapy clinical trials
Below are recruiting concurrent chemoradiotherapy clinical trials, each written for real people, not researchers. We’re tracking 70 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07566156RecruitingPhase 3
New drug combination vs. radiation for bladder cancer preservation
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) work better than radiation with chemotherapy for muscle-invasive bladder cancer. The goal is to treat your cancer while keeping your bladder instead of removing it.
Santa Barbara, CaliforniaAges 18 years+ - NCT07559786RecruitingPhase 2
Adebrelimab after chemo-radiation for limited-stage small cell lung cancer
This trial tests whether the drug adebrelimab (a type of immunotherapy) can help prevent your lung cancer from coming back after you finish chemotherapy and radiation. It is for people with limited-stage small cell lung cancer (cancer found only in one lung and nearby lymph nodes) that did not grow during initial treatment.
Zhengzhou, HenanAges 18–75 - NCT04910347RecruitingPhase 2
Nivolumab after chemoradiation for advanced nasopharyngeal cancer
This trial tests nivolumab (an immune system–boosting antibody) given after standard chemoradiation to help keep advanced nasopharyngeal cancer from coming back or progressing. It may help your immune system better find and attack cancer cells after treatment.
SeoulAges 19 years+ - NCT07154069RecruitingPhase 3
Immunotherapy for advanced nasopharyngeal cancer after chemo
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
Guangzhou, GuangdongAges 18–65 - NCT06364384RecruitingPhase 2
Chemo, radiation, and immunotherapy for rectal squamous cell carcinoma
This trial tests a combination of chemotherapy (cisplatin and 5-FU), radiation, and an immunotherapy drug (PD-1 antibody) for people with a rare type of rectal cancer that hasn't spread. The goal is to see if this treatment can shrink or eliminate the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07125755RecruitingPhase 3
Comparing Chemo plus Radiation vs. Radiation Alone for Head and Neck Cancer
This trial tests whether adding chemotherapy to radiation therapy after surgery can help prevent head and neck cancer from coming back. It is for people who have certain risk factors after their surgery but no signs of cancer spread.
Guangzhou, GuangdongAges 18–70 - NCT07622797RecruitingPhase 2
Immunotherapy with chemotherapy and radiation for esophageal cancer
This trial tests a new immunotherapy drug (camrelizumab) combined with standard chemotherapy and radiation to treat advanced esophageal cancer while avoiding surgery if possible. The goal is to shrink the tumor and help you keep your esophagus working.
Luoyang, HenanAges 18 years+ - NCT06129864RecruitingPhase 3
Study of Volrustomig for advanced head and neck cancer after chemoradiation
This trial tests a new drug called volrustomig (MEDI5752) for people with advanced head and neck cancer that was not removed by surgery and has been treated with chemoradiation. The goal is to see if the drug can help prevent the cancer from coming back.
Birmingham, AlabamaAges 18–130 - NCT07338487RecruitingPhase 1
Nanocrystalline megestrol acetate with chemoradiation for advanced cervical cancer
This trial tests a newer form of megestrol acetate (a medication that can help with appetite and weight) given alongside standard chemotherapy and radiation for locally advanced cervical cancer that cannot be removed by surgery. The study aims to see if this combination is safe and effective.
Changsha, HunanAges 18 years+ - NCT05527470RecruitingPhase 3
Chemo then radiation for newly diagnosed advanced nasopharyngeal cancer
This Phase 3 trial tests giving chemotherapy first, then either radiation alone or chemotherapy together with radiation. It aims to improve treatment control for people with newly diagnosed, advanced nasopharyngeal cancer.
Guilin, GuangxiAges 18–65 - NCT05957016RecruitingPhase 2
New treatment before and during rectal radiation with chemo
This Phase 2 study tests a treatment plan given before surgery (neoadjuvant) along with radiation and chemotherapy (concurrent chemoradiotherapy) for locally advanced rectal cancer. It may help shrink the cancer before the next steps of care and improve control of the disease.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05980715RecruitingPhase 3
Comparing immunotherapy to radiation after successful treatment for head and neck cancer
This trial looks at whether giving an immunotherapy drug (a PD-1 inhibitor) after surgery is better than giving radiation therapy for people with advanced head and neck cancer who had a complete response to chemotherapy and immunotherapy before surgery. The goal is to prevent the cancer from coming back.
Guangzhou, GuangdongAges 18–65 - NCT06251388RecruitingPhase 2
Chemoradiation plus Cadonilimab for advanced cervical cancer
This trial tests whether adding an immunotherapy drug called Cadonilimab (AK104) to standard chemoradiation can help people with locally advanced cervical cancer that has not spread to distant organs. The goal is to improve treatment outcomes for those who cannot have surgery.
Chengdu, SichuanAges 18–75 - NCT06341595RecruitingPhase 2
Chemo, radiation and immunotherapy before surgery for stomach cancer with PALM
This trial tests combining chemotherapy, radiation, and an immunotherapy drug (sintilimab) before surgery for advanced stomach cancer that has spread to lymph nodes near the aorta (called PALM). The goal is to see if this approach can shrink the tumor enough to allow complete removal.
Nanjing, JiangsuAges 18–75 - NCT06354218RecruitingPhase 2
Serplulimab plus chemoradiation for older adults with esophageal cancer
This trial tests a new immunotherapy drug called serplulimab combined with standard chemotherapy and radiation for older adults with locally advanced esophageal cancer. It aims to see if this combination can help shrink tumors and improve outcomes without prior cancer treatment.
Nanjing, JiangsuAges 75 years+ - NCT06455410RecruitingPhase 2
GP plus adebrelimab vs. chemo alone for nasopharyngeal cancer
This trial tests a new combination of chemotherapy drugs (GP) plus an immunotherapy drug (adebrelimab) before standard treatment for nasopharyngeal cancer. It aims to see if this combination works better than chemotherapy alone for shrinking tumors.
Foshan, GuangdongAges 18–65 - NCT07601737RecruitingPhase 2
Nimotuzumab with immunotherapy and chemotherapy for head and neck cancer
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
ShanghaiAges 18–75 - NCT06510660RecruitingPhase 2
Immunotherapy and Chemoradiation for Advanced Esophageal Cancer
This trial tests a combination of immunotherapy (adebrelimab) plus standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if adding the immunotherapy before and during chemoradiation helps control the cancer better.
Fuzhou, FujianAges 18–70 - NCT06569459RecruitingPhase 2
Trilaciclib with chemoradiation and immunotherapy for esophageal cancer
This trial tests an investigational drug called trilaciclib added to standard chemoradiation and immunotherapy for locally advanced esophageal cancer that cannot be surgically removed. The goal is to see if this combination improves treatment outcomes.
Nanjing, JiangsuAges 18 years+ - NCT06601309RecruitingPhase 2
Study of treatments before surgery for esophageal cancer
This trial is testing different treatment combinations before surgery for people with locally advanced esophageal squamous cell carcinoma. The goal is to find which approach works best based on specific biomarkers like PD-L1 levels.
Fuzhou, FujianAges 18–75 - NCT06709417RecruitingPhase 2
Immunotherapy plus chemo and radiation for advanced esophageal cancer
This trial is testing whether giving a combination of an immunotherapy drug (sintilimab) with chemotherapy, followed by radiation plus more chemotherapy (concurrent chemoradiotherapy), can help people with advanced esophageal cancer that cannot be removed surgically. The goal is to see if this approach shrinks the tumor and improves outcomes.
Shanghai, Shanghai MunicipalityAges 20–75 - NCT06792786Recruiting
Study of Chemo-Immunotherapy and Radiation for Esophageal Cancer with Blood Monitoring
This study tests a combination of chemotherapy, immunotherapy, and radiation for esophageal cancer that cannot be surgically removed. It also uses a simple blood test (ctDNA) to monitor your cancer's response throughout treatment.
Jinhua, ZhejiangAges 18–75 - NCT06849167RecruitingPhase 2
Immunotherapy with low-dose chemoradiation for advanced lung cancer
This trial tests combining immunotherapy with a shorter course of chemoradiation for locally advanced non-small cell lung cancer that hasn't spread. It aims to see if this approach is more effective and tolerable than standard treatment.
BeijingAges 18–70 - NCT06851247RecruitingPhase 2
Chemoradiation plus toripalimab for advanced nasopharyngeal cancer
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
Guangzhou, GuangdongAges 18–65
Hear when a new Concurrent Chemoradiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for concurrent chemoradiotherapy?
- Yes. Clin2 currently lists 70 recruiting concurrent chemoradiotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a concurrent chemoradiotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a concurrent chemoradiotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.